Skip to main content
. 2019 Jul 31;21(12):1529–1539. doi: 10.1093/neuonc/noz127

Fig. 5.

Fig. 5

Combination of afatinib and thalidomide prolongs survival of intracranial immune-competent tumor-bearing mice. (A) Western blot analysis of EGFR expression in GL261 and GL261EGFRwt cell lines. β-actin was used as a loading control. (B) Ten days after intracranial injection of GL261EGFRwt cells (clone 1) into C57BL/6 mice, the mice were divided into 4 groups: vehicle, afatinib (50 mg/kg), thalidomide (150 mg/kg), and afatinib plus thalidomide (n = 5). Comparison was made between combination group and afatinib group; P = 0.020.